Brainsway
Jerusalem · Founded 2003
About Brainsway
Brainsway's patented breakthrough technology launches a new era in brain disorder treatment. A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide. Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's treatment was approved by the FDA for Major Depressive Disorder patients*. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks. Brainsway's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway is dedicated to research and continuously explores treatments for a variety of brain disorders.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $85.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2024)
- Ticker: tlv:BRIN
- Website: brainsway.com
- Phone: +972 8552003867
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/brainsway-134401 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.